Revolution Medicines (RVMD) Set to Announce Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.05. The business’s revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.72) EPS. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Stock Performance

Revolution Medicines stock opened at $45.64 on Thursday. Revolution Medicines has a fifty-two week low of $15.44 and a fifty-two week high of $48.61. The company has a market cap of $7.53 billion, a PE ratio of -12.17 and a beta of 1.44. The business’s 50-day simple moving average is $40.98 and its two-hundred day simple moving average is $35.50.

Analyst Upgrades and Downgrades

RVMD has been the topic of a number of recent research reports. Bank of America upped their target price on Revolution Medicines from $48.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. HC Wainwright upped their target price on Revolution Medicines from $44.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Jefferies Financial Group assumed coverage on Revolution Medicines in a report on Monday, July 8th. They issued a “buy” rating and a $63.00 price target for the company. Barclays upped their price target on Revolution Medicines from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Finally, Needham & Company LLC upped their price target on Revolution Medicines from $46.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $50.67.

Insider Buying and Selling

In related news, CFO Jack Anders sold 10,000 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $40.03, for a total value of $400,300.00. Following the completion of the transaction, the chief financial officer now directly owns 101,959 shares in the company, valued at $4,081,418.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Sushil Patel sold 2,155 shares of the firm’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $44.00, for a total transaction of $94,820.00. Following the completion of the transaction, the director now directly owns 19,948 shares in the company, valued at $877,712. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jack Anders sold 10,000 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $40.03, for a total value of $400,300.00. Following the completion of the sale, the chief financial officer now owns 101,959 shares in the company, valued at $4,081,418.77. The disclosure for this sale can be found here. Over the last three months, insiders sold 58,421 shares of company stock worth $2,578,577. Company insiders own 8.00% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.